Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 12/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.62 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.48 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.48 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosfluconazole SCHEMBL27638104 | 0.99 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fosfluconazole SCHEMBL27971502 | 0.99 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL14193097 | 0.91 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL14221883 | 0.89 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fosfluconazole SCHEMBL5450058 | 0.88 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL10296768 | 0.88 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL10066654 | 0.83 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL10034136 | 0.83 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL14193103 | 0.83 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| SCHEMBL10034138 | 0.82 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719384-A2 | COMPOUNDS WITH ANTIFUNGAL PROPERTIES | Trustees of Dartmouth College (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2024249290-A2 | COMPOUNDS WITH ANTIFUNGAL PROPERTIES | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240196882-A1 | PRESERVATION SOLUTION, PRESERVATION SYSTEM AND METHOD FOR PRESERVING BIOLOGICAL TISSUES IN VITRO, IN PARTICULAR CORNEAL TISSUES | AL.CHI.MI.A. S.R.L. (IT) | 2024-06-20 | — | — | US | claimed |
| US-20240172743-A1 | PRESERVATION SOLUTION, PRESERVATION SYSTEM AND METHOD FOR PRESERVING BIOLOGICAL TISSUES IN VITRO, IN PARTICULAR CORNEAL TISSUES | AL.CHI.MI.A. S.R.L. (IT) | 2024-05-30 | — | — | US | claimed |
| EP-4368020-A1 | PRESERVATION SOLUTION, PRESERVATION SYSTEM AND METHOD FOR PESERVING BIOOLOGICAL TISSUES | AL.CHI.MI.A. S.r.l. (IT) | 2024-05-15 | — | — | EP | claimed |
| EP-4368021-A1 | PRESERVATION SOLUTION, PRESERVATION SYSTEM AND METHOD FOR PRESERVING BIOOLOGICAL TISSUES IN VITRO, IN PARTICULAR CORNEAL TISSUES | AL.CHI.MI.A. S.r.l. (IT) | 2024-05-15 | — | — | EP | claimed |
| CN-111171075-B | Preparation method of fosfluconazole | 北京四环生物制药有限公司 | 2022-07-12 | — | — | CN | claimed |
| WO-2022124342-A1 | AGENT FOR CANCER THERAPY, AND SCREENING METHOD FOR ACTIVE INGREDIENT THEREOF | 国立大学法人 岡山大学 | 2022-06-16 | — | — | WO | claimed |
| CN-113559264-A | Methods of treating microbial infections including mastitis | 罗达制药公司 | 2021-10-29 | — | — | CN | claimed |
| CN-113144197-A | Method of treating topical microbial infections | 罗达制药公司 | 2021-07-23 | — | — | CN | claimed |
| EP-1534721-B1 | PROCESS FOR CONTROLLING THE HYDRATE MIX OF THE DISODIUM SALT OF FOSFLUCONAZOLE | PFIZER LTD (GB) | 2006-07-26 | — | — | EP | claimed |
| US-6977302-B2 | Triazole derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2005-12-20 | — | — | US | claimed |
| EP-1534721-A1 | PROCESS FOR CONTROLLING THE HYDRATE MIX OF A COMPOUND | Pfizer Limited (GB) | 2005-06-01 | — | — | EP | claimed |
| US-20040236105-A1 | Triazole derivatives useful in therapy | PFIZER, INC. | 2004-11-25 | — | — | US | claimed |
| WO-2004007507-A1 | PROCESS FOR CONTROLLING THE HYDRATE MIX OF A COMPOUND | PFIZER LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| US-20040007689-A1 | Process for controlling the hydrate mix of a compound | PFIZER INC. | 2004-01-15 | — | — | US | claimed |
| US-20030144250-A1 | Triazole derivatives useful in therapy | GREEN STUART (GB) | 2003-07-31 | — | — | US | claimed |
| EP-0880533-B1 | Triazole derivatives useful in therapy | PFIZER RES & DEV (IE) | 2002-06-12 | — | — | EP | claimed |
| EP-0880533-A1 | TRIAZOLE DERIVATIVES USEFUL IN THERAPY | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-12-02 | — | — | EP | claimed |
| WO-1997028169-A1 | TRIAZOLE DERIVATIVES USEFUL IN THERAPY | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-08-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144250-A1 | Triazole derivatives useful in therapy | CYP51A1, THOP1, ERG28 | CYP3A4 87/4885CYP2C9 301/4885CYP2C19 202/4885 |
| US-20240196882-A1 | PRESERVATION SOLUTION, PRESERVATION SYSTEM AND METHOD FOR PRESERVING BIOLOGICAL TISSUES IN VITRO, IN PARTICULAR CORNEAL TISSUES | CRYAB, CRYZ, CRYAA | CYP3A4 4766/4885CYP2C9 4767/4885CYP2C19 4852/4885 |
| US-20040236105-A1 | Triazole derivatives useful in therapy | CYP51A1, ERG28, THOP1 | CYP3A4 42/4885CYP2C9 227/4885CYP2C19 140/4885 |
| US-20240172743-A1 | PRESERVATION SOLUTION, PRESERVATION SYSTEM AND METHOD FOR PRESERVING BIOLOGICAL TISSUES IN VITRO, IN PARTICULAR CORNEAL TISSUES | CRYAB, CRYZ, CRYAA | CYP3A4 4616/4885CYP2C9 4703/4885CYP2C19 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.